MARKET

PRGO

PRGO

Perrigo Co Plc
NYSE
38.06
+1.53
+4.19%
After Hours: 37.59 -0.47 -1.23% 18:28 10/04 EDT
OPEN
36.78
PREV CLOSE
36.53
HIGH
38.17
LOW
36.78
VOLUME
1.14M
TURNOVER
0
52 WEEK HIGH
49.39
52 WEEK LOW
30.90
MARKET CAP
5.12B
P/E (TTM)
-58.1069
1D
5D
1M
3M
1Y
5Y
FDA Says Continuing, Under Conditions, To Exercise Enforcement Discretion On Importation, Sale In Domestic Commerce Of Certain Baby Formula Products; FDA
FDA Published Guidance To Help Provide A Pathway For Infant Formulas Operating Under Enforcement Discretion In The U.S. To Remain On The Market -Reuters
Benzinga · 4d ago
FDA Says Report Highlights Findings And Recommendations That Will Support Agency's Ongoing Efforts To Ensure Our Most Vulnerable Population Has Consistent Access To Infant And Specialty Formula Products In Future
-Dow Jones
Benzinga · 09/20 19:26
US FDA Commits to Strengthening Infant Formula Supply
US FDA Commits to Strengthening Infant Formula Supply
MT Newswires · 09/20 14:57
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
Benzinga · 09/14 14:07
Perrigo raised to Buy at Argus; expects momentum to continue amid self-care focus
Argus Research upgraded OTC product maker Perrigo Company plc (NYSE:PRGO</...
Seekingalpha · 09/14 13:53
Argus Research Upgrades Perrigo to Buy, Announces $46 Price Target
Argus Research analyst Kristina Ruggeri upgrades Perrigo (NYSE:PRGO) from Hold to Buy and announces $46 price target.
Benzinga · 09/14 12:23
--Argus Upgrades Perrigo to Buy From Hold; Price Target is $46
--Argus Upgrades Perrigo to Buy From Hold; Price Target is $46
MT Newswires · 09/14 08:01
FDA Schedules AdComm Review For First Over The Counter Birth Control Pill
Benzinga · 09/13 10:40
More
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.

Webull offers kinds of Perrigo Company PLC stock information, including NYSE:PRGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRGO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRGO stock methods without spending real money on the virtual paper trading platform.